Álvarez-Díaz Diego A, Laiton-Donato Katherine, Franco-Muñoz Carlos, Mercado-Reyes Marcela
Unidad de Secuenciación y Genómica, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, D.C., Colombia; Grupo de Salud Materna y Perinatal, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, D.C., Colombia.
Unidad de Secuenciación y Genómica, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, D. C., Colombia.
Biomedica. 2020 Oct 30;40(Supl. 2):188-197. doi: 10.7705/biomedica.5841.
The COVID-19 pandemic caused by SARS-CoV-2 is a public health problem on a scale unprecedented in the last 100 years, as has been the response focused on the rapid genomic characterization of SARS-CoV-2 in virtually all regions of the planet. This pandemic emerged during the era of genomic epidemiology, a science fueled by continued advances in next-generation sequencing. Since its recent appearance, genomic epidemiology included the precise identification of new lineages or species of pathogens and the reconstruction of their genetic variability in real time, evidenced in past outbreaks of influenza H1N1, MERS, and SARS. However, the global and uncontrolled scale of this pandemic created a scenario where genomic epidemiology was put into practice en masse, from the rapid identification of SARS-CoV-2 to the registration of new lineages and their active surveillance throughout the world. Prior to the COVID-19 pandemic, the availability of genomic data on circulating pathogens in several Latin America and the Caribbean countries was scarce or nil. With the arrival of SARS-CoV-2, this scenario changed significantly, although the amount of available information remains scarce and, in countries such as Colombia, Brazil, Argentina, and Chile, the genomic information of SARS-CoV-2 was obtained mainly by research groups in genomic epidemiology rather than the product of a public health surveillance policy or program. This indicates the need to establish public health policies aimed at implementing genomic epidemiology as a tool to strengthen surveillance and early warning systems against threats to public health in the region.
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病大流行是过去100年来规模空前的公共卫生问题,在全球几乎所有地区对SARS-CoV-2进行快速基因组特征分析的应对措施也是如此。这场大流行出现在基因组流行病学时代,这是一门由下一代测序技术的不断进步推动的科学。自其近期出现以来,基因组流行病学包括精确识别病原体的新谱系或新物种,并实时重建其遗传变异性,这在过去的甲型H1N1流感、中东呼吸综合征和严重急性呼吸综合征疫情中得到了体现。然而,这场大流行的全球范围和不受控制的规模造成了一种局面,即从SARS-CoV-2的快速识别到新谱系的登记及其在全球的主动监测,基因组流行病学得到了大规模应用。在2019冠状病毒病大流行之前,拉丁美洲和加勒比地区的几个国家关于传播性病原体的基因组数据很少或根本没有。随着SARS-CoV-2的出现,这种情况发生了显著变化,尽管可用信息仍然很少,而且在哥伦比亚、巴西、阿根廷和智利等国,SARS-CoV-2的基因组信息主要是由基因组流行病学研究小组获得的,而不是公共卫生监测政策或计划的产物。这表明需要制定公共卫生政策,将基因组流行病学作为一种工具,以加强该地区针对公共卫生威胁的监测和预警系统。